Fragile X protein may play role in Alzheimer’s disease

A brain afflicted by severe Alzheimer's disease is a sad sight, a wreck of tangled neural connections and organic rubble as the lingering evidence of a fierce internal battle.

A new study has now uncovered an unexpected link between this devastating neural degeneration and a protein whose absence causes a different neurological disease - the inherited mental retardation disorder called fragile X syndrome. In the Feb. 13 issue of the journal Public Library of Science Biology, University of Wisconsin-Madison researchers report that, in mice, the fragile X mental retardation protein may regulate the material responsible for the plaques and cell death seen in the brains of Alzheimer's patients. If similar research can be confirmed in humans, it offers a glimmer of hope for developing a treatment for Alzheimer's disease.

The telltale plaques of Alzheimer's disease contain remnants of dying cells and clumps of a small, sticky scrap of a protein called beta-amyloid. When the gummy protein builds up in the brain, it can band together and wreak havoc inside neurons, damaging and ultimately killing them.

No one knows what triggers toxic beta-amyloid accumulation in the brain, but the sticky bits are made when the larger amyloid precursor protein is chopped up by enzymes, says Jim Malter, a pathologist in the UW-Madison School of Medicine and Public Health and senior author of the new study. Scientists have long hoped to prevent or treat Alzheimer's disease by keeping the amyloid precursor protein in check: less precursor should mean less of the dangerous pieces, which in turn should mean less cell death.

The current study pinpoints the fragile X mental retardation protein as an important player in this control. Malter and colleague Cara Westmark found that it normally restricts production of the full-length amyloid precursor in mice, releasing the protein's synthesis template only when the nerve cell is stimulated. By linking protein synthesis to neural activity, this regulation helps the brain cement useful connections while ignoring or eliminating worthless ones.

However, Malter and Westmark found that mice lacking the fragile X protein lost this level of control over the amyloid precursor and, subsequently, had much higher levels of the toxic beta-amyloid in their brains.

Links between developmental disabilities and degenerative disease do make sense, Malter says. Mental retardation and cognitive decline can reflect similar underlying problems, such as difficulties forming or maintaining correct neural pathways. Malter explains that the amyloid precursor protein was already known to be important at the sites of connections between neural cells and unusually high levels have been reported in patients with other developmental disorders, including autism and Down's syndrome.

While the new finding does not mean that the fragile X protein is directly involved in Alzheimer's disease, Malter says the result highlights a possible target for therapy. "Right now, there are no good drugs for Alzheimer's disease," he says. "The idea of reducing beta-amyloid seems sound in terms of treatment."

Rather than target the fragile X protein itself, Malter envisions using drugs to block a cell-surface receptor, a gateway to the cell that kicks off the fragile X protein's response to neural stimulation. In fact, he says, several drugs targeting the receptor already exist, originally developed decades ago as anti-anxiety treatments. He plans to start testing these compounds in mice to see if they can reduce build-up of the toxic protein.

If such drugs are effective against dangerous protein accumulation, they might be used for patients in the early stages of Alzheimer's to prevent disease progression. Though unlikely to reverse existing Alzheimer's symptoms, Malter says, "Keeping people at the same place would be a victory."

Source: by Jill Sakai, University of Wisconsin-Madison

Related stories:

New Membrane Model May Unlock Secrets of Early-Stage Alzheimer's
Researchers at the National Institute of Standards and Technology and three collaborating institutions are using a new laboratory model of the membrane surrounding neurons in the brain to study how a protein long suspected of a role in early-stage Alzheimer’s disease actually impairs a neuron’s structure and function. The team’s findings are reported in a new paper in the Biophysical Journal.
Scientists demonstrate means of reducing Alzheimer's-like plaques in fly brain
Neuroscientists at Cold Spring Harbor Laboratory (CSHL) are part of a collaboration that has succeeded in demonstrating that overexpression of an enzyme in the brain can reduce telltale deposits causally linked with Alzheimer's disease.
Study identifies toxic key to Alzheimer’s disease memory loss
Using new scientific techniques, scientists have unlocked the cascade of molecular events that lead to Alzheimer’s disease. The scientific findings published in the latest edition of Nature Medicine suggest a potential new target for the development of drug therapies to fight the irreversible and degenerative disease which affects some 29.8 million people worldwide. The total worldwide societal cost of dementia was estimated at somewhere in the region of US$315.4 billion in 2005.

NVIDIA Announced New Geforce GTX 200 GPUs
Imagine instead of taking over five hours to convert a video for your iPod, it only takes 35 minutes. Imagine using your PC to simulate protein folding to help find a cure for debilitating diseases. Imagine that your PC can dramatically accelerate everyday tasks, and deliver an exciting visual experience in the process.
Mechanism explains link between apolipoprotein E and Alzheimer's disease
Scientists have discovered a previously unknown mechanism by which apolipoprotein E, a molecule whose mutation is linked to Alzheimer's disease (AD), stimulates degradation of sticky amyloid beta (A-beta) protein within the brain. The research, published by Cell Press in the June 12 issue of the journal Neuron, may lead to a powerful new therapy for this devastating disease.
Gene variation linked to earlier onset of Alzheimer's symptoms
Investigators at Washington University School of Medicine in St. Louis have identified a genetic variation associated with an earlier age of onset in Alzheimer's disease.
How to construct a 'firefly' worm
Research describing a new modified luminescent worm that allows, for the first time, to measure, in real time, the metabolism of an entire living organism has just been published in the journal BMC Physiology.
Vaccine triggers immune response, prevents Alzheimer's
A vaccine created by University of Rochester Medical Center scientists prevents the development of Alzheimer’s disease-like pathology in mice without causing inflammation or significant side effects.

News discussion:

Medicine & Health news